Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vactosertib + Nal-IRI/FL in Metastatic PDAC
NCT04258072Phase 1Unknown
- Sponsor
- Samsung Medical Center
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vactosertib in pancreatic adenocarcinoma (PDAC), sponsored by Samsung Medical Center. Primary endpoints: Recommended Phase 2 Dose and Safety and Tolerability. Status: unknown.
02
Drugs
vactosertib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04258072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04258072.